Canadian Bioceutical Closes First Tranche of Equity Private Placement

The Canadian Bioceutical Corporation (TSXV:BCC) announced that it has received approval from the TSX Venture Exchange to complete the first tranche of an equity private placement.

As quoted in the press release:

Specifically, 978,572 common shares will be issued, each at a price of $0.35, to raise $342,500 of new equity financing.

As announced on May 4, 2015, it is anticipated that the gross proceeds of the Private Placement will be used as to seventy percent (70%) allocated to fund BCC’s plans to expand its existing life sciences business into the production, processing and distribution of medical marijuana and cannabis-based medicinal products (including in relation to the build out of the manufacturing facility located in the City of Owen Sound, Ontario) and thirty percent (30%) allocated for general working capital purposes.

Additional details in relation to BCC’s plan to enter into the medical marijuana sector may be found in the company’s two (2) News Releases of January 7, 2015.

Scott Boyes, CEO of Canadian Bioceutical, commented:

The fact that we are able to raise equity financing above our current share price demonstrates considerable confidence in our team and our business plan. We continue to consider consummating the financing of the remaining $157,500 tranche in the coming days, but may instead proceed with other, potentially more attractive, financing opportunities.

Click here to read the full Canadian Bioceutical Corporation (TSXV:BCC) press release.